explore -WSS

explore

author：fashion 2025-08-11 08:00:57 - browse：1322

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： SAMSHA loosens regulations on methadone treatment centers

knowledge

hotspot

WSS

Vertex non

Novo Nordisk to expand supply of Wegovy for U.S. patients

Covid misinformation case heads to Supreme Court

Woodcock on FDA’s accelerated approval and her next chapter

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Quicker fix for pulse oximeters urged during FDA public meeting

Wikipedia

explore

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

JPM 2024: Nvidia claims we're in biological revolution. Are we?

ChatGPT in medicine: STAT answers readers' burning questions

The SUPPORT Act is critical to fighting the opioid crisis

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: live from JPM 2024

The high cost of giving birth even with insurance

Idaho abortion case may prompt more restrictions in other states

Heart attack and stroke risk calculators need revising

How I ended up pumping milk in a bathroom stall at JPM 2024

Wikipedia

Idaho abortion case may prompt more restrictions in other states

Vertex non

General Catalyst, Summa Health deal will turn on physician buy

Some dementia cases could be undiagnosed liver disease

Three issues to watch in global health in 2024

Health and fitness trackers are measuring the wrong things

explore

knowledge

hotspot

focus